Stock Analysis
Kura Oncology, Inc. (KURA) Stock Analysis
Kura Oncology, Inc. (KURA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Kura Oncology, Inc. (KURA) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 70/100. Risk is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
KURA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $7.77 |
| AIQ Score | 47/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $697.88M |
| P/E Ratio (TTM) | -2.35 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.78 |
| Revenue (Q3 FY2026) | $22.84M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.33 |
| Volume | 2.23M |
| 52-week range | $6.75-$13.90 |
| RSI 14 | 37.1 |
| 50-Day SMA | $10.17 |
| 200-Day SMA | $9.77 |
| Analyst Price Target | $24.00 |
| Next Earnings | Mar 4, 2027 |
KURAKura Oncology, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum40
- Value70
- Quality45
- Risk resilience39
- Sentiment—
KURA Stock Analysis Summary
Kura Oncology, Inc. (KURA) currently has an AIQ Score of 47/100, indicating a bearish setup. Value is the strongest factor at 70/100. Risk resilience is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, KURA has AIQ Score of 47/100 with Value base of 70/100 and fading Risk resilience at 39/100. Wait for component alignment before adding exposure.
Value (70/100) leads while Risk resilience (39/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 4.58% stock move · KURA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is KURA Bullish or Bearish Right Now?
KURA currently has a bearish overall setup. Value is the strongest factor at 70/100, while Risk Resilience is weakest at 39/100. The current evidence suggests a bearish setup.
- - Analyst target implies +208.88% upside from the latest quote.
- - Momentum is weak at 40/100.
- - Risk Resilience is weak at 39/100.
- - Price is -20.51% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (35 vs 3).
Current Consensus
KURA's Technical Analysis Consensus is currently Strong Sell, with 3 buy, 8 neutral, and 35 sell votes. KURA's 14-day RSI is 37.1, which places the stock in a weaker momentum range. KURA's beta is 1.33, indicating greater market sensitivity than the broad market.
What Changed in KURA?
The largest recent change in KURA is Momentum moving down by 23.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the KURA Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
KURA Decision Framework
Public evidence layers, setup checks, and risk context for Kura Oncology, Inc..
Kura Oncology, Inc. (KURA) Stock Analysis
Kura Oncology, Inc. has an AIQ Score of 47/100 in a Bearish regime. Value is strongest at 70/100. Beta is 1.33, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | KURA is in a Bearish AIQ regime with score 47/100. |
| Signal Conflict | The primary conflict is that value leads at 70/100 while risk lags at 39/100. |
| Factor Evidence | Momentum 40/100 · Value 70/100 · Quality 45/100 · Risk 39/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 70/100.
Momentum is 40/100 and RSI (14) is 37.1.
KURA is in a Bearish regime at 47/100.
Risk factor is 39/100 with beta 1.33 and annual volatility 63.01%.
Current conflict: value leads at 70/100 while risk lags at 39/100.
KURA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
KURA Fundamentals
KURA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
KURA Technical Analysis
KURA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
KURA Stock Catalysts
Track KURA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
KURA Dividend Analysis
KURA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
KURA Financial Data
KURA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
KURA Risk Analysis
KURA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
KURA Stock News
KURA stock news, market tone, recent headlines, and catalyst context.
KURA vs Biotechnology Peers
Current peer cohort: KURA · KYMR · LGND · MAZE · MBX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| KURA Current stock | 47/100 | 70/100 | 40/100 | 39/100 | -0.25 | 63.01% | Current |
| KYMR Kymera Therapeutics, Inc. | 65/100 | 43/100 | 87/100 | 60/100 | 1.33 | 63.12% | KURA vs KYMR |
| LGND Ligand Pharmaceuticals Incorporated | 76/100 | 61/100 | 86/100 | 70/100 | 1.25 | 36.55% | KURA vs LGND |
| MAZE Maze Therapeutics, Inc. | 59/100 | 42/100 | 83/100 | 47/100 | 0.41 | 67.20% | KURA vs MAZE |
| MBX MBX Biosciences, Inc. Common Stock | 68/100 | — | 71/100 | 50/100 | 1.42 | 77.34% | KURA vs MBX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for KURA: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching KURA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for KURA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
KURA Stock FAQ
What is KURA stock price today?
Kura Oncology, Inc.'s current stock price is $7.77. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is KURA bullish or bearish right now?
KURA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is KURA's market cap?
KURA's market cap is $697.88M based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is KURA's current P/E ratio?
KURA's current P/E ratio is -2.35 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is KURA's RSI?
KURA's 14-day RSI is 37.1 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is KURA above its 50-day and 200-day moving averages?
KURA is -23.59% from its 50-day SMA and -20.51% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is KURA's next earnings date?
KURA's next earnings date is currently listed as Mar 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does KURA pay a dividend?
KURA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.